Physician profile
Carla Perry
NPI 1265940936
$3,313.64
in general payments reported to CMS, 2019-2025
34 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $415 · 2023: $1,651 · 2024: $825 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,444 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.79 |
| Education | $156.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $454.20 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Incyte Corporation | $258.42 | 2021-2024 | Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $228.91 | 2022-2024 | Iclusig, Ninlaro |
| Pfizer INC. | $214.08 | 2024 | |
| Merck Sharp & Dohme LLC | $207.55 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $199.60 | 2022-2024 | |
| Janssen Biotech, INC. | $198.80 | 2023-2024 | Darzalex, Imbruvica, Erleada |
| Abbvie INC. | $163.75 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $143.79 | 2021-2023 | Onivyde |
| Pharmacosmos Therapeutics INC. | $124.99 | 2022 | |
| Janssen Scientific Affairs, LLC | $108.20 | 2022 | |
| Daiichi Sankyo INC. | $104.56 | 2023-2024 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $91.71 | 2023-2024 | Lynparza, Calquence |
| Genentech USA, INC. | $82.07 | 2021-2024 | Alecensa, Tecentriq, Rozlytrek |
| Pharmacyclics LLC, An Abbvie Company | $80.81 | 2022-2023 | Imbruvica |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $69.24 | 2022-2024 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $65.76 | 2023-2024 | Libtayo |
| Tempus Ai, INC | $58.91 | 2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $53.85 | 2023-2024 | |
| Glaxosmithkline, LLC. | $52.98 | 2022-2024 | Jemperli, Zejula |
| Stemline Therapeutics INC. | $51.73 | 2023-2024 | Orserdu |
| Gilead Sciences, INC. | $49.14 | 2022-2024 | Trodelvy |
| Astellas Pharma US INC | $44.29 | 2022-2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $28.94 | 2023 | |
| Celgene Corporation | $23.85 | 2023 | Opdualag |
| G1 Therapeutics, INC. | $19.48 | 2023 | Cosela |
| Adc Therapeutics America, INC. | $18.49 | 2023 | |
| Lilly USA, LLC | $18.40 | 2023 | Jaypirca, Verzenio |
| Karyopharm Therapeutics INC. | $17.94 | 2024 | Xpovio |
| Amgen INC. | $17.06 | 2023 | Lumakras |
| Deciphera Pharmaceuticals INC. | $16.49 | 2023 | Qinlock |
| Alexion Pharmaceuticals, INC. | $16.17 | 2024 | Ultomiris |
| Puma Biotechnology, INC. | $15.28 | 2023 | |
| Exelixis INC. | $14.20 | 2023 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.